Human parainfluenza virus type 3 (PI3 virus) causes mild to severe respiratory tract infection in infants (1, 2, 4, 5, 10) . PI3 virus is an enveloped RNA virus and possesses two glycoproteins, hemagglutinin-neuraminidase (HN) and fusion (F), at its external surface. These two glycoproteins are known to be responsible for initiation and progress of the infection process (6, 16, 17) . We have demonstrated that subcutaneous immunization of hamsters with two glycoproteins can confer protection from challenge infection with prototype live virus (14) . The importance of antibodies to the HN and F glycoproteins for prevention of infection by parainfluenza viruses has already been documented (3, 9) . These studies with simian virus 5 (SV5) have shown that antibodies specific for the HN glycoprotein were effective only in preventing spread of infection in a system where little cell fusion occurs and in which spread of virus is facilitated through released progeny virions. On the other hand, antibody to the F glycoprotein was capable of completely preventing the spread of infection in cells susceptible to virus-induced fusion as well as in cells resistant to fusion. Serological studies with naturally infected children have demonstrated that the appearance of antibodies to both the HN and F glycoproteins of P13 virus correlates with protection from infection (8) . We have recently reported the purification of the two P13 virus glycoproteins by immunoaffinity chromatography with specific monoclonal antibodies (15) . The study presented here was aimed at determining the contribution of the individual glycoproteins in induction of a protective immune response against challenge infection with live P13 virus. (14) .
MATERIALS AND METHODS

Virus
Purified virus glycoproteins. Virus envelope glycoproteins HN and F were purified from P13 virus-infected LLC-MK2 cell lysates by affinity chromatography with specific monoclonal antibodies by the procedure described recently (15) . The purified glycoproteins were used for reconstitution into phosphatidyl choline vesicles for subsequent immunization of experimental animals.
Immunization and challenge infection of hamsters. Fourweek-old hamsters were procured from Charles River Breeding Laboratories (Wilmington, Mass.) and immunized with either of the two virus envelope glycoproteins alone or mixed together by the subcutaneous or intranasal route as described (14 mals showed bright immunofluorescence, whereas lungs collected from hamsters showing protection to challenge infection contained little or no viral antigen (Fig. 2) .
Protective role of monospecific rabbit antibodies to HN and F following passive transfer. Initially, a large group of baby hamsters (7 days old) were infected intranasally with 103 PFU of P13 virus to study its replication pattern at different times after infection. Four hamsters from the group were sacrificed at 24-h intervals, and their lungs and tracheal homogenates were tested separately to determine the virus titer (Fig. 3) . Lungs from infected baby hamsters showed similar virus titers up to day 6. On the other hand, virus titers in tracheas could not be detected until day 2, after which similar virus titers were observed up to day 6. Thus, P13 virus showed a more prolonged replication pattern in baby hamsters than in young adult (4-week-old) hamsters (14) . Passive transfer of rabbit antibody to either HN or F in baby hamsters conferred weak protection from challenge infection ( Table 2) . A 7-fold reduction in virus titer with rabbit anti-HN and about 25-fold reduction with rabbit anti-F antibodies were observed compared with the control infected group of animals. However, passive transfer of a mixture of an equal volume of these two antisera resulted in about a 200-fold reduction in virus titer following challenge infection with live virions. Inoculation of higher quantities of rabbit immunoglobulin did not show any significant further change in virus recovery.
DISCUSSION genate
Two potentially important surface glycoproteins, HN and F, were purified from parainfluenza virus-infected cell lymnogonsto sates by immunoaffinity chromatography. The purified glycoproteins were shown to retain their biological activities as tested with monospecific rabbit antiserum by hemagglutina-A 0 tion inhibition, virus neutralization, and inhibition of cell fusion activities (15 (15) . In the present study, glycoprotein-lipid vesicles were used for VOL. 62, 1988 on October 19, 2017 by guest http://jvi.asm.org/ Downloaded from determining the role of individual glycoproteins in induction of a protective immune response in hamsters. The results presented here suggest that immunization with HN or F elicited similar antibody responses to the respective glycoproteins, as tested by ELISA or immunoprecipitation. However, titers of virus-neutralizing antibody were higher in serum and bronchial lavage samples from animals immunized with a mixture of the two glycoproteins. Challenge infection of these immunized animals demonstrated that neither of these two virus envelope glycoproteins alone induced a significant level of protection when administered subcutaneously or intranasally in hamsters. On the other hand, animals immunized with both glycoproteins showed complete protection, as none of the animals from this group showed any detectable virus in lung and tracheal homogenates following challenge infection with PI3 virus. These animals also showed little or no evidence of virus when lung sections were examined by immunofluorescence.
In recent studies with the pneumovirus respiratory syncytial virus with vaccinia virus recombinants expressing G and F or affinity-purified glycoproteins, it was demonstrated that either of the envelope glycoproteins can induce a high level of protection to challenge infection (12, (18) (19) (20) . The G glycoprotein of respiratory syncytial virus was reported to induce a less complete protective response to challenge by homologous virus and provided less complete cross-subgroup protection. On the other hand, the F glycoprotein had a predominant role in conferring immunity to challenge infection by both homologous and heterologous virus strains (7) . Evidence was also obtained that affinity-purified F glycoprotein of canine distemper virus may suffice as an immunogen against the disease (11) . In another recent report, a vaccinia virus recombinant expressing F of SV5 was shown to induce higher levels of neutralizing antibody than did a vaccinia virus-HN recombinant. However, animals inoculated with vaccinia virus-HN were better protected from challenge infection with SV5. It was suggested that for SV5 there may be a qualitative difference in the in vivo properties of the neutralizing antibodies induced by the vaccinia virus-F and -HN viruses (13) . Our results following immunization with either of the P13 virus glycoproteins alone or in combination showed similar antibody responses in serum and bronchial lavage samples, although there was a significant difference in resistance to infection. A moderate level of protection was also observed following passive transfer of antibodies to both glycoproteins. The effect of combined antibodies appeared to be more than additive, as the reduction of virus titer was about 10-to 25-fold higher than that obtained by passive transfer of antibody directed to either the HN or F glycoprotein alone.
The possibility of partial denaturation of the two glycoprotein antigens during the isolation procedure cannot be eliminated. However, consideration was given to this possibility, and the glycoprotein antigens used for combined immunization were from the same preparations used for immunization with the individual glycoproteins. The complete protection observed following immunization with the mixture of HN and F is correlated with higher levels of antibodies to viral glycoproteins in bronchial lavage samples than were observed after immunization with each glycoprotein alone. These results suggest that HN and F may act synergistically to elicit a protective immune response against parainfluenza virus infection. It is possible that the glycoproteins have immunomodulating properties, and further detailed studies with paramyxovirus glycoproteins may lead to better understanding of the mechanisms of protection.
